Trials / Completed
CompletedNCT02308020
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 162 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abemaciclib | Administered orally |
Timeline
- Start date
- 2015-04-20
- Primary completion
- 2018-11-08
- Completion
- 2019-11-08
- First posted
- 2014-12-04
- Last updated
- 2020-12-19
- Results posted
- 2019-12-19
Locations
44 sites across 9 countries: United States, Australia, Austria, Belgium, Canada, France, Israel, Italy, Spain
Source: ClinicalTrials.gov record NCT02308020. Inclusion in this directory is not an endorsement.